Tag: M.W:200-300

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-94-5,4-(Iodomethyl)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

101691-94-5, Reference Example 3 methyl 2-[1-methyl-5-(methylsulfanyl)-1H-pyrazol-3-yl]-3-(tetrahydro-2H-pyran-4-yl)propanoate [Show Image] To a solution of diisopropylamine (4.0 mL) in tetrahydrofuran (60 mL) was slowly added 1.6M hexane solution (16.1 mL) of n-butyllithium at -70C under a nitrogen atmosphere. The reaction mixture was stirred at -70C for 15 min, and a solution of methyl [1-methyl-5-(methylsulfanyl)-1H-pyrazol-3-yl]acetate (4.68 g) in tetrahydrofuran (5 mL) was slowly added thereto. The reaction mixture was stirred at – 70C for 15 min, and 4-(iodomethyl)tetrahydro-2H-pyran (5.80 g) was added thereto. The mixture was stirred overnight at room temperature. To the reaction mixture was added 10% aqueous citric acid solution, and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated brine, dried (MgSO4), and concentrated. The obtained residue was subjected to silica gel column chromatography to give the title compound (2.57 g, yield 37%) as a pale-yellow oil from the fraction eluted with ethyl acetate-hexane (1:1, volume ratio). MS:299(MH+).

As the paragraph descriping shows that 101691-94-5 is playing an increasingly important role.

Reference£º
Patent; Takeda Pharmaceutical Company Limited; EP2266983; (2010); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.141095-78-5,2-Bromo-1-(tetrahydro-2H-pyran-4-yl)ethanone,as a common compound, the synthetic route is as follows.

A suspension of 150 mg (0.591 mmol) of (8S)-2-chloro-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 578.13 mg (1.77 mmol) of cesium carbonate in 10 mL of acetonitrile is stirred for 15 minutes at room temperature. 146.97 mg (0.709 mmol) of 2-bromo-1-(tetrahydropyran-4-yl)ethanone are then added. After stirring overnight at room temperature, the reaction mixture is evaporated and the residue is taken up in water and extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and evaporated to dryness to give 220 mg of (8S)-2-chloro-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one, corresponding to the following characteristics: LC/MS (method G): ESI+ [M+H]+: m/z 380 tr (min)=1.94 1H NMR (300 MHz, delta in ppm, CDCl3): 1.58-2.04 (m, 2H), 2.37 (m, 1H), 2.5 (m, 1H), 2.76 (m, 1H), 3.5 (4H), 3.9 (d, 1H), 3.96-4.02 (m, 4H), 4.6 (m, 1H), 5.25 (d, 1H), 5.99 (s, 1H).

141095-78-5, As the paragraph descriping shows that 141095-78-5 is playing an increasingly important role.

Reference£º
Patent; El-Ahmad, Youssef; Filoche-Romme, Bruno; Ganzhorm, Axel; Marciniak, Gilbert; Muzet, Nicolas; Ronan, Baptiste; Vivet, Bertrand; Zerr, Veronique; US2015/183804; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

1408168-76-2, Potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a 4 mL vial was added bis(di-tert-butyl(4-dimethylaminophenyl)phosphine) dichloro-palladium(II) (5.0 mg, 7.0 mumol), Cs2CO3 (137 mg, 0.422 mmol), tert-butyl 4-(5-chloro-6-methoxythieno[3,2-b]pyridin-2-yl)-4-oxobutanoate (50.0 mg, 0.141 mmol), and potassium trifluoro(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)borate (39.8 mg, 0.169 mmol). To the vial was added toluene (0.50 mL) and water (0.10 mL). The vial was degassed with N2 for 5 min. The mixture was heated to 100 C. for 18 h. Upon cooling to RT, the mixture was filtered through CELITE, and the CELITE was washed with EtOAc. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (0?75% EtOAc gradient in Hex) to afford tert-butyl 4-(6-methoxy-5-(2-((tetrahydro-2H-pyran-2-yl)oxy) ethyl)thieno[3,2-b]pyridin-2-yl)-4-oxobutanoate. LCMS (C23H32NO6S) (ES, m/z): 450 [M+H]+. 1H NMR (500 MHz, CDCl3) delta 8.45 (s, 1H), 7.80 (s, 1H), 4.71 (s, 1H), 4.26-4.15 (m, 1H), 4.04 (s, 3H), 3.78 (t, J=8.3 Hz, 1H), 3.65-3.42 (m, 4H), 3.33 (t, J=6.3 Hz, 2H), 2.73 (t, J=6.3 Hz, 2H), 1.64-1.48 (m, 6H), 1.46 (s, 9H)., 1408168-76-2

As the paragraph descriping shows that 1408168-76-2 is playing an increasingly important role.

Reference£º
Patent; Merck Sharp & Dohme Corp.; Altman, Michael D.; Cash, Brandon D.; Childers, Matthew Lloyd; Cumming, Jared N.; DeMong, Duane E.; Haidle, Andrew Marc; Henderson, Timothy J.; Jewell, James P.; Larsen, Matthew A.; Lim, Jongwon; Lu, Min; Otte, Ryan D.; Trotter, Benjamin Wesley; US2019/300513; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

To a solution of 224 g (0.83 mol) of Compound 7 in methyl isobutylketone (1.6 L) are added 189 g (1.66 mol) of potassium thioacetate. The beige suspension is stirred at 70 C. for 4.5 h. The reaction mixture is cooled to room temperature and water (1.8 L) is added. The organic layer is washed with 10% aqueous K2CO3 solution (1.8 L) and water (1 L). The organic layer is filtered through Celite (20 g), activated charcoal (20 g) and Na2SO4 (20 g) and the filtrate is concentrated under reduced pressure. The residual oil is azeotroped with methylcyclohexane (200 mL) and n-heptanes (250 mL) to afford 138 g of Compound 8 as a yellow-orange oil. Yield: 96%; ES-MS: m/z 175 [M+H]; 1H NMR (400 MHz, CHLOROFORM-d) delta ppm 1.23-1.40 (2H, m), 1.59-1.78 (3H, m), 2.33 (3H, d, J=4.16 Hz), 2.82 (2H, dd, J=6.24, 3.79 Hz), 3.27-3.39 (2H, m), 3.88-4.02 (2H, m)., 101691-65-0

Big data shows that 101691-65-0 is playing an increasingly important role.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2011/71196; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.53911-68-5,4-(4-Chlorophenyl)dihydro-2H-pyran-2,6(3H)-dione,as a common compound, the synthetic route is as follows.

The solution of commercial 2,4-dichloro-6-nitroaniline (621 mg) and 3-(4- chlorophenyl)glutaric anhydride (674 mg) in 1,4-dioxane (2 ml) was heated to reflux shortly and stirred at rt for Ih. The solvent was removed by distillation and the residue dried in vacuo. The oily residue was dissolved in acetic acid (6 ml) and heated to reflux. Iron powder (1.01 g) was added and the mixture stirred under reflux for 1 h. Then cone. HCI (6 ml) was added cautiously and the green-yellow solution was refluxed for additional 2 h. All volatiles were removed at the water aspirator and the residue precipitated from acetic acid/cone. HCI solution with water. The solid was collected by suction filtration and washed well with IM HCI and water. The crude was recrystallised from acetic acid to give 4-(5,7-dichloro-2- benzimidazolyl)-3-(4-chlorophenyl)butanoic acid HCI (325 mg) as colourless crystals.1H-NMR (500 MHz, DMSOd5): delta (ppm) = 2.70 (dd, J = 16.2, 8.9 Hz, IH), 2.79 (dd, J = 16.2, 5.9 Hz, IH), 3.35 (dd, J = 14.7, 8.3 Hz, IH), 3.43 (dd, J = 14.7, 7.6 Hz, IH), 3.83 (m, IH), 7.33 (q, J = 8.6 Hz, 4H), 7.59 (d, J = 1.6 Hz, IH), 7.73 (d, J = 1.6 Hz, IH).13C-NMR and DEPT (125 MHz, DMSOd6) : delta (ppm) = 33.39 (CH2), 39.39 (CH), 39.46 (CH2), 112.58 (CH), 119.26 (C), 123.64 (CH), 128.28 (2 CH), 128.63 (C), 129.14 (2 CH), 131,1 (br, C), 131,29 (C), 134.40 (C), 141.22 (C), 154.96 (C), 172.24 (CO). MS ( + ESI): m/z = 383 (M + H)., 53911-68-5

The synthetic route of 53911-68-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UNIVERSITAET DES SAARLANDES; ENGEL, Matthias; FROeHNER, Wolfgang; STROBA, Adriane; BIONDI, Ricardo M.; WO2010/43711; (2010); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

33821-94-2, 2-(3-Bromopropoxy)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a mixture of 4-iodo-1H-pyrazole (2.0 g, 10.3 mmol) and Cs CO(5.04 g, 15.5 mmol) in MeCN (28 mL) was added 2-(3-bromopropoxy)tetrahydro-2H-pyran ( 1.84 mL, 10.8 mmol) and the mixturestirred at T overnight. The crude reaction mixture was poured into water andextracted with EtOAc (x 3). The combined organic layers were washed withbrine, dried (MgSO4) and concentrated in vacuo. The resulting residue waspurified by FCC, using a gradient of 0-80% EtOAc in cyclohexane, to give thetitle compound (2.95 g, 81%)., 33821-94-2

The synthetic route of 33821-94-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CHIESI FARMACEUTICI S.P.A.; Alcaraz, Lilian; Panchal, Terry Aaron; Jennings, Andrew Stephen Robert; Cridland, Andrew Peter; Hurley, Christopher; (80 pag.)KR2016/16973; (2016); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1098184-12-3,(S)-2-(((Benzyloxy)carbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid,as a common compound, the synthetic route is as follows.

tert-Butyl(3S,8aR)-3-[(1R)-1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl]hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate (380 mg) obtained in Example 5 (ii) was dissolved in 4M hydrogen chloride-ethyl acetate solution (5 mL), and the solution was stirred at room temperature for 18 hr. The precipitate resulting from the reaction mixture was collected by filtration. To the collected precipitate were added tetrahydrofuran (5 mL), N-ethyl-N-(1-methylethyl)propan-2-amine (0.497 mL), (2S)-{[(benzyloxy)carbonyl]amino}(tetrahydro-2H-pyran-4-yl)ethanoic acid (418 mg) and 1-hydroxybenzotriazole (218 mg). To this mixture was added 1-ethyl-3-3-dimethylaminopropyl)carbodiimide hydrochloride (310 mg), and the mixture was stirred at room temperature for 18 hr. To the reaction mixture was added water (50 mL), and the mixture was extracted with ethyl acetate (200 mL). The organic layer was washed with saturated brine (50 mL), dried over anhydrous magnesium sulfate, and filtered, and the filtrate was concentrated to give an oil. This oil (500 mg) was dissolved in methanol (3 mL), 20% palladium-carbon (100 mg, 20 wt %) was added thereto, and the mixture was stirred at room temperature for 4 hr under a hydrogen atmosphere (3 atm). The insoluble material was filtered off through a celite pad, and the filtrate was concentrated to give an oil., 1098184-12-3

1098184-12-3 (S)-2-(((Benzyloxy)carbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid 66926961, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; US2011/34469; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-94-5,4-(Iodomethyl)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

Step 3 [0341] 4-(Iodomethyl)tetrahydro-2H-pyran obtained in Step 2 (0.940 g, 4.16 mmol) was dissolved in acetonitrile (10 mL), triphenylphosphine (1.09 g, 4.16 mmol) was added thereto, and the mixture was stirred for 13 hours under reflux with heating. The solvent in the reaction mixture was evaporated under reduced pressure, diethyl ether was added to the residue, and the precipitated crystal was collected by filtration, whereby triphenyl[(tetrahydro-2H-pyran-4-yl)methyl]phosphonium iodide (0.600 g, 30%) was obtained. 1H NMR (300 MHz, DMSO-d6, delta): 7.90-7.74 (m, 15H), 3.68-3.61 (m, 4H), 3.16-3.13 (m, 2H), 2.02-1.91 (m, 1H), 1.41-1.31 (m, 4H)., 101691-94-5

The synthetic route of 101691-94-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kyowa Hakko Kirin Co., Ltd.; FURUTA, Takayuki; SAWADA, Takashi; DANJO, Tomohiro; NAKAJIMA, Takahiro; UESAKA, Noriaki; EP2881394; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics